Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。